 |
 |
SIB 1508Y was developed by SIBIA and is in PhasII clinical trials. This biotech company has done similar research for Alzhemer's. > J Pharmacol Exp Ther 1999 Aug;290(2):731-9 > > Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive > functioning in chronic low-dose MPTP-treated monkeys. > > Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK > Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson > University, Philadelphia, Pennsylvania. > > Monkeys that receive chronic low-dose 1-methyl-4-phenyl-1,2,3, > 6-tetrahydropyridine (MPTP) administration have difficulty performing > numerous cognitive tasks. This study further examines the extent to which > chronic low-dose MPTP exposure affects performance of a visual memory task > [variable delayed response (VDR)] with both attentional and short-term > memory components and assesses the effects of the novel neuronal nicotinic > acetylcholine receptor agonist SIB-1508Y and levodopa on cognitive task > performance. Before MPTP treatment, these monkeys displayed a > delay-dependent decrement in performance on the VDR task and performed well > on delayed matching-to-sample and visual pattern discrimination tasks. > Chronic low-dose MPTP treatment caused a shift to a delay-independent > pattern of responding on the VDR task, such that short-delay trials were > performed as poorly as long-delay trials. There were also deficits in > performing the delayed matching-to-sample task, whereas visual > discrimination performance remained intact. SIB-1508Y normalized the pattern > of response on the VDR task by significantly improving performance on > short-delay trials and on the delayed matching-to-sample task. These effects > lasted up to 24 to 48 h after SIB-1508Y administration. Neither levodopa nor > nicotine significantly improved task performance. These results suggest that > chronic low-dose MPTP exposure results in a cognitive disturbance that can > be corrected by the nicotinic acetylcholine receptor agonist SIB-1508Y but > not by levodopa. Thus, SIB-1508Y may be useful in the treatment of the > cognitive deficits in Parkinson's disease. > > PMID: 10411585, UI: 99340176 > ---------------------------------------------------------------------------- > ----